利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.025 秒)

    Method of producing sustained-release preparation
    1.
    发明授权
    Method of producing sustained-release preparation 失效
    缓释制剂的制备方法

    公开(公告)号：US5534269A

    公开(公告)日：1996-07-09

    申请号：US270838

    申请日：1994-07-05

    申请人： Yasutaka Igari ,  Kazumichi Yamamoto ,  Kayoko Okamoto ,  Yutaka Yamagata

    发明人： Yasutaka Igari ,  Kazumichi Yamamoto ,  Kayoko Okamoto ,  Yutaka Yamagata

    IPC分类号： A61K9/16 ,  A61K9/52 ,  A61K9/14

    CPC分类号： A61K9/1694 ,  A61K9/1647 ,  Y10S514/964

    摘要： A method of producing a sustained-release preparation which includes permitting a water-soluble polypeptide to permeate into a biodegradable matrix in the aqueous solution. The production method of the present invention makes possible the permeation of a water-soluble polypeptide into a biodegradable matrix without bringing the water-soluble polypeptide into contact with an organic solvent. Hence the water-soluble polypeptide is prepared without affecting the water-soluble polypeptide bioactivity and is thus effective for use as a pharmaceutical.

    摘要翻译： 一种制备缓释制剂的方法，其包括使水溶性多肽渗透到水溶液中的可生物降解的基质中。 本发明的制备方法使水溶性多肽渗入可生物降解的基质成为可能，而不会使水溶性多肽与有机溶剂接触。 因此，制备水溶性多肽而不影响水溶性多肽生物活性，因此有效地用作药物。

    Sustained-release preparation
    3.
    发明授权
    Sustained-release preparation 失效

    公开(公告)号：US06376461B1

    公开(公告)日：2002-04-23

    申请号：US09426716

    申请日：1999-10-26

    申请人： Yasutaka Igari ,  Yutaka Yamagata ,  Satoshi Iinuma ,  Hiroaki Okada ,  Kazumichi Yamamoto

    发明人： Yasutaka Igari ,  Yutaka Yamagata ,  Satoshi Iinuma ,  Hiroaki Okada ,  Kazumichi Yamamoto

    IPC分类号： A01N3718

    CPC分类号： A61K9/5031 ,  A61K9/0019 ,  A61K31/00 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/212 ,  A61K38/27 ,  A61K38/28

    摘要： According to a first embodiment, there is provided a sustained-release preparation comprising a water-insoluble or slightly water-soluble polyvalent metal salt of a water-soluble physiologically active substance which is not an endothelin antagonist, and a biodegradable polymer. The sustained-release preparation of the first embodiment is highly efficient in incorporating the water-soluble physiologically active substance and suppresses the initial burst of the water-soluble physiologically active substance. The sustained-release preparation of the present invention is capable of releasing the water-soluble physiologically active substance while retaining its bioactivity after administration in vivo. Furthermore, the water-soluble physiologically active substance in the sustained-release preparation is kept stable for a long period of time, with little loss of bioactivity. According to a second embodiment, there is provided a sustained-release preparation comprising an anti-endothelin substance and a biodegradable polymer. The sustained-release preparation of the present invention sustainedly releases an anti-endothelin substance, serving well in the treatment of endothelin-associated diseases.

    Matrix for sustained-release preparation
    4.
    发明授权
    Matrix for sustained-release preparation 失效
    用于缓释制剂的基质

    公开(公告)号：US5665394A

    公开(公告)日：1997-09-09

    申请号：US723152

    申请日：1996-09-30

    申请人： Yasutaka Igari ,  Akira Saikawa ,  Kayoko Okamoto ,  Shigeru Kamei ,  Masahisa Oka ,  Atsunori Sano

    发明人： Yasutaka Igari ,  Akira Saikawa ,  Kayoko Okamoto ,  Shigeru Kamei ,  Masahisa Oka ,  Atsunori Sano

    IPC分类号： A61K9/16 ,  C08G63/06 ,  A61K9/50 ,  A61F2/02 ,  A61F9/02 ,  A61K9/48

    CPC分类号： C08G63/06 ,  A61K9/1647

    摘要： The present invention relates to a matrix for sustained-release preparation comprising an ester formed at a terminal carboxyl group of a straight-chain polyester which essentially consists of an .alpha.-hydroxymonocarboxylic acid. The matrix is stable to light, heat, moisture, coloring etc., and is of low toxicity. The sustained-release preparation produced by using the ester of the present invention offers stable drug release over an extended period of time, ensuring sustained stable effect. Furthermore, the sustained-release preparation does not show excess drug release just after administration.

    摘要翻译： 本发明涉及用于缓释制剂的基质，其包含在直链聚酯的末端羧基上形成的酯，其基本上由α-羟基单羧酸组成。 基质对光，热，水分，着色等均稳定，毒性低。 通过使用本发明的酯制备的缓释制剂在延长的时间内提供稳定的药物释放，确保持续的稳定的效果。 此外，缓释制剂在施用后不显示过量的药物释放。

    SUSTAINED RELEASE COMPOSITIONS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF
    6.
    发明申请
    SUSTAINED RELEASE COMPOSITIONS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF 审中-公开
    可持续发行组合物，其生产方法和使用方法

    公开(公告)号：US20080014237A1

    公开(公告)日：2008-01-17

    申请号：US11782707

    申请日：2007-07-25

    申请人： Yasutaka Igari ,  Yoshio Hata ,  Kazumichi Yamamoto

    发明人： Yasutaka Igari ,  Yoshio Hata ,  Kazumichi Yamamoto

    IPC分类号： A61K9/00 ,  A61K38/02 ,  A61K38/09 ,  A61K47/12

    CPC分类号： A61K9/1647 ,  A61K9/0024 ,  A61K9/1617

    摘要： Sustained release compositions containing a physiologically active substance or its salt, hydroxynaphthoic acid or its salt and a lactic acid-glycolic polymer or its salt, wherein the product of the weight-average molecular weight of the lactic acid-glycolic acid polymer by the amount (μmol) of the terminal carboxyl group per unit mass (g) of the lactic acid-glycolic acid polymer is from 1,200,000 to 3,000,000 (inclusive); and their production; medicaments containing these sustained release compositions, etc.

    摘要翻译： 含有生理活性物质或其盐，羟基萘甲酸或其盐和乳酸 - 乙醇酸聚合物或其盐的缓释组合物，其中乳酸 - 乙醇酸聚合物的重均分子量乘以（ 乳酸 - 乙醇酸聚合物的单位质量（g）的末端羧基的摩尔数为1,200,000〜300万以上） 和他们的生产; 含有这些缓释组合物的药物等

    Sustained release compositions, process for producing the same and use thereof
    7.
    发明授权
    Sustained release compositions, process for producing the same and use thereof 失效
    缓释组合物，其制备方法及其用途

    公开(公告)号：US07265157B1

    公开(公告)日：2007-09-04

    申请号：US10019786

    申请日：2000-07-13

    申请人： Yasutaka Igari ,  Yoshio Hata ,  Kazumichi Yamamoto

    发明人： Yasutaka Igari ,  Yoshio Hata ,  Kazumichi Yamamoto

    IPC分类号： A61K47/12 ,  A61K38/00

    CPC分类号： A61K9/1647 ,  A61K9/0024 ,  A61K9/1617

    摘要： Sustained release compositions containing a physiologically active substance or its salt, hydroxynaphthoic acid or its salt and a lactic acid-glycolic polymer or its salt, wherein the product of the weight-average molecular weight of the lactic acid-glycolic acid polymer by the amount (μmol) of the terminal carboxyl group per unit mass (g) of the lactic acid-glycolic acid polymer is from 1,200,000 to 3,000,000 (inclusive); and their production; medicaments containing these sustained release compositions, etc.

    摘要翻译： 含有生理活性物质或其盐，羟基萘甲酸或其盐和乳酸 - 乙醇酸聚合物或其盐的缓释组合物，其中乳酸 - 乙醇酸聚合物的重均分子量乘以（ 乳酸 - 乙醇酸聚合物的单位质量（g）的末端羧基的摩尔数为1,200,000〜300万以上） 和他们的生产; 含有这些缓释组合物的药物等